A Phase 1/2 interventional study of Lurbinectedin and Dostarlimab in Endometrial Cancer, sponsored by Vall d'Hebron Institute of Oncology. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by Vall d'Hebron Institute of Oncology · Phase 1/2, Interventional, and Treatment
Background:
Endometrial cancer is a prevalent gynecological malignancy, with a significant number of cases diagnosed at an advanced stage or recurring following initial treatment. Platinum-based chemotherapy represents a standard treatment option for these patients; however, disease progression often occurs, highlighting the need for novel therapeutic approaches. Lurbinectedin, a synthetic analog of marine alkaloid-derived compounds, and dostarlimab, a monoclonal antibody targeting PD-1, have demonstrated promising antitumor activity in various malignancies. This phase I-II clinical trial seeks to evaluate the safety, tolerability, and efficacy of combining lurbinectedin and dostarlimab in patients with advanced or recurrent endometrial cancer who have experienced disease progression following platinum-based chemotherapy.
Primary Objectives:
To determine the maximum tolerated dose (MTD) and recommended dose for further investigation of lurbinectedin and dostarlimab in combination therapy for advanced or recurrent endometrial cancer.
To assess the antitumor activity of lurbinectedin and dostarlimab combination therapy, measured by objective response rate (ORR), in patients with advanced or recurrent endometrial cancer.
Secondary Objectives:
To evaluate the safety and tolerability of lurbinectedin and dostarlimab combination therapy in patients with advanced or recurrent endometrial cancer.
To characterize the pharmacokinetic profile of lurbinectedin and dostarlimab when administered in combination therapy.
To explore pharmacogenomic biomarkers predictive of response and/or resistance to lurbinectedin and dostarlimab combination therapy in patients with advanced or recurrent endometrial cancer.
To assess progression-free survival (PFS), duration of response (DOR), clinical benefit rate (CBR), and overall survival (OS) in patients receiving lurbinectedin and dostarlimab combination therapy for advanced or recurrent endometrial cancer.
To investigate the impact of lurbinectedin and dostarlimab combination therapy on quality of life and symptom control in patients with advanced or recurrent endometrial cancer.
This study is a phase I-II clinical trial conducted to evaluate the safety, tolerability, and efficacy of lurbinectedin and dostarlimab combination therapy in patients with advanced or recurrent endometrial cancer. The trial follows a multicenter, open-label design and comprises two phases: a dose escalation phase (Phase I) and an expansion phase (Phase II). The primary endpoints include determining the maximum tolerated dose (MTD), recommended dose for further investigation, and objective response rate (ORR). Secondary endpoints encompass safety, pharmacokinetics, pharmacogenomics, progression-free survival (PFS), duration of response (DOR), clinical benefit rate (CBR), overall survival (OS), and quality of life assessments.
Study Treatments:
Lurbinectedin: Lurbinectedin is administered as a lyophilized powder for concentrate for infusion, reconstituted with sterile water for injection to achieve a concentration of 0.5 mg/mL. The initial dose for infusion is 2.6 mg/m\^2, diluted in either 5% glucose solution or 0.9% sodium chloride solution. During Phase I, dose adjustments are based on body surface area calculated using the DuBois formula.
Dostarlimab: Dostarlimab is supplied in vials containing 500 mg at a concentration of 50 mg/mL. The recommended dose is a fixed dose of 500 mg administered intravenously over 30 minutes. Treatment cycles consist of administration on Day 1 of a 21-day cycle, with dostarlimab followed by lurbinectedin in combination therapy.
During the dose escalation phase (Phase I), a predefined dose escalation scheme is employed, starting with dose level (DL) -1 and progressing to DL1, DL2, and subsequent levels as per the protocol. Dose escalation is guided by the occurrence of dose-limiting toxicities (DLTs) and the determination of the MTD. Once the MTD is established, the expansion phase (Phase II) begins, wherein additional patients receive treatment at the recommended dose to further evaluate safety and efficacy outcomes.
1,325 studies on the registry are indexed under Endometrial Neoplasms; 447 are open to participants now.
This study's planned enrollment of 15 is below the median of 70 across 941 interventional studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →Vall d'Hebron Institute of Oncology is the lead sponsor of 21 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Lurbinectedin · Drug: Dostarlimab
participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
Maximum Tolerated Dose (MTD) and Recommended Dose (RD) Determination
This measure involves identifying the highest dose of lurbinectedin in combination with dostarlimab that can be administered without causing unacceptable toxicity. The recommended dose for further evaluation in Phase II will also be determined.
Time frame: MTD and RD will be assessed during the Phase I portion of the study, the time frame will be arround 6 months.
Evaluation of Lurbinectedin and Dostarlimab Combination Therapy in Advanced/Recurrent Cervical Cancer Patients
This objective aims to assess the efficacy of lurbinectedin in combination with dostarlimab in advanced or recurrent cervical cancer patients who have experienced disease progression after platinum-based chemotherapy. The primary objective is to evaluate the confirmed tumor response rate, as defined by RECIST v1.1 criteria, in patients without alterations in the MMR system.
Time frame: This objective will be assessed during the Phase II portion of the study, the time frame will be arround 6 months.
Safety Evaluation of Lurbinectedin in combination with Dostarlimab
Safety will be assessed by monitoring adverse events (AEs) using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
Time frame: Safety evaluations will occur throughout the study, starting from the first dose administration and continuing until the end of the study, an average of 1 year
Evaluate the progression-free survival (PFS)
Evaluate the time from study entry until disease progression or death from any cause.
Time frame: These efficacy endpoints will be evaluated throughout the study, with regular assessments during follow-up visits, up to 1 year
Pharmacokinetic (PK) and Pharmacogenomic Evaluation
PK parameters will be assessed to determine the drug's concentration in plasma over time.
Time frame: PK and pharmacogenomic evaluations will occur at specified time points during the study (12 months).
Overall Response Rate (ORR)
The proportion of patients with a complete or partial response to treatment, assessed by RECIST v.1.1 criteria, specifically in the Phase II portion of the study.
Time frame: ORR will be assessed after completion of treatment cycles and response evaluations according to RECIST v.1.1 criteria(1 year).
Evaluate the Duration of Response (DOR)
The objective is to analyse the time from the first documented response until disease progression or death.
Time frame: Safety evaluations will occur throughout the study, starting from the first dose administration and continuing until the end of the study, an average of 1 year
Evaluate the Clinical Benefit Rate (CBR)
The objective is to examinate the time from study entry until death from any cause. Survival Rates: The percentage of patients who survive at specified time points (6, 12, 18, and 24 months)
Time frame: Safety evaluations will occur throughout the study, starting from the first dose administration and continuing until the end of the study, an average of 24 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vall d'Hebron Institute of Oncology